Zoekresultaten - 9 results

Nationwide quality assurance of high-throughput diagnostic molecular testing during the SARS-CoV-2 pandemic: role of the Belgian National Reference Centre.

diagnostic assays for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) and later to assess the quality of commercial kits. To meet the growing demand for decentralised testing, both clinical ...

Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay.

(e.g. virus neutralization assays), or are expensive with suboptimal specificity (e.g. commercial ELISA s and RDT s). Bead-based assays offer a cost-effective alternative and allow for multiplexing to ...

New QSAR models to predict chromosome damaging potential based on the in vivo micronucleus test

overall better performance than existing free and commercial models for the same endpoint, while demonstrating high coverage. Health Topics:  Health and disease monitoring Surveillance de la santé et des ...

Biological monitoring of exposure to pesticide residues among Belgian florists

compounds and metabolites) in their urines. A total of 42 urine samples (24-h urines) were collected from florists during their professional activities, on the three most important commercial periods. The ...

Historical aspects of iodine deficiency control.

where iodine deficiency is now adequately controlled, and identify at-risk population where it is not. The goal should be now global eradication of severe iodine deficiency. Commercial distribution of ...

Biological activity conferred by endocrine disrupting chemicals in hospital effluent and river water from the Brussels Region, Belgium

hospital effluent and, respectively, 52.3 and 1.2ng EEQ /L for WWTP influent and effluent. For comparison reasons, commercial drinking waters amount to 0.004-0.070 ng EEQ /L. These results indicate that ...

Batch release of vaccines in Europe: from method transfer to first commercial batch available on the market. Straightforward approach that requires a proactive mindset of the manufacturer.

sometimes a lengthy process. Sometimes more than one year should be taken into account between the intention of putting a vaccine on the market and the first available commercial batch. Since OCABR in EU is ...

QR code

QR code for this page URL